Secreted LGALS3BP can inhibit colon cancer progression through binding to CD9/CD82, which suppresses Wnt/beta-catenin signaling via an ISG15-dependent proteasomal-ubiquitination mechanism [148]. This evidence concerns the gene LGALS3BP and malignant colon neoplasm.